Stevanato Group (NYSE:STVN) Announces Quarterly Earnings Results

Stevanato Group (NYSE:STVN) announced its quarterly earnings data on Tuesday. The company reported €0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of €0.17 by (€0.01), FiscalAI reports. Stevanato Group had a net margin of 11.24% and a return on equity of 10.62%. The firm had revenue of €326.06 million for the quarter.

Here are the key takeaways from Stevanato Group’s conference call:

• Third-quarter results were solid: revenue rose 8% organically to €326.1 million, adjusted EBITDA increased 14% to €88.8 million, and the adjusted EBITDA margin expanded 150 basis points to 27.2%.
• Management reiterated full-year 2026 guidance, including revenue of €1.26–€1.28 billion, adjusted EBITDA of €335–€345.2 million, and adjusted diluted EPS of €0.60–€0.62; stronger BDS growth is expected to offset a lower engineering outlook.
• The company expects a temporary moderation in 2027 growth because one GLP-1 customer is reducing Nexa syringe volumes; management now expects low-single-digit growth rather than its longer-term high-single-digit to low-double-digit target, although it says most of the shortfall has been backfilled.
• Non-GLP biologics revenue grew more than 30% in the quarter and 13% year to date, while demand remains strong for Alba syringes, EZ-fill cartridges and vials, and delivery devices; management expects broader biologics and biosimilars demand to support a return to normalized growth beyond 2027.
• Engineering revenue fell 12% as customer orders were delayed, and management acknowledged that order conversion remains below target; the company is also evaluating the segment’s strategic role because its visual inspection and assembly activities are dilutive to corporate margins.

Stevanato Group Stock Performance

NYSE:STVN traded up €0.34 during mid-day trading on Thursday, hitting €13.79. The stock had a trading volume of 1,223,069 shares, compared to its average volume of 537,997. The stock has a market capitalization of $4.17 billion, a price-to-earnings ratio of 23.54, a P/E/G ratio of 1.16 and a beta of 0.80. The company has a 50 day simple moving average of €20.17 and a 200-day simple moving average of €18.07. Stevanato Group has a 52 week low of €12.05 and a 52 week high of €27.00. The company has a current ratio of 1.61, a quick ratio of 1.08 and a debt-to-equity ratio of 0.21.

Trending Headlines about Stevanato Group

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Some results offered an offset: reports said third-quarter revenue beat expectations and the bottom line improved year over year. Stevanato Group Q3 2026: Big Revenue Beat, Cautious 2027 Outlook
• Neutral Sentiment: Citigroup lowered its price target from $26 to $20 but kept a Buy rating, signaling continued optimism alongside more cautious valuation expectations. Benzinga analyst update
• Negative Sentiment: The earnings update highlighted that GLP-1 revenue declined in the quarter to about 17%–18% of company sales. Stevanato also expects only low-single-digit growth in 2027, with lower GLP-1 syringe volumes linked to one customer. This outlook appears to be the key source of investor concern. Stevanato expects low single-digit growth in 2027
• Negative Sentiment: Stevanato missed the consensus earnings-per-share estimate, and its shares fell below their 200-day moving average after the report—both signs of near-term pressure. UBS cut its target from $23 to $16 and kept a Neutral rating, while William Blair downgraded the stock to Market Perform. William Blair downgrade
• Negative Sentiment: Several law firms announced investigations into whether Stevanato’s disclosures complied with securities laws, focusing on the GLP-1 revenue disclosure. These are investigations, not findings of wrongdoing, but may add uncertainty and reputational risk. Investor investigation announcement

Insider Activity

In other news, CFO Marco Dal Lago sold 4,209 shares of Stevanato Group stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of €20.09, for a total transaction of €84,558.81. Following the sale, the chief financial officer owned 81,144 shares of the company’s stock, valued at approximately €1,630,182.96. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mauro Stocchi sold 13,649 shares of the stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of €21.50, for a total value of €293,453.50. Following the completion of the transaction, the insider directly owned 400,000 shares of the company’s stock, valued at €8,600,000. This trade represents a 3.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,926 shares of company stock worth $459,738 in the last quarter. Company insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP acquired a new stake in Stevanato Group in the second quarter worth about $22,621,000. Ranger Investment Management L.P. bought a new position in Stevanato Group in the 2nd quarter valued at about $21,438,000. Cooper Investors PTY Ltd. increased its stake in Stevanato Group by 4.4% during the 2nd quarter. Cooper Investors PTY Ltd. now owns 668,494 shares of the company’s stock valued at $12,080,000 after buying an additional 28,265 shares during the period. Schwartz Investment Counsel Inc. increased its stake in Stevanato Group by 15.0% during the 3rd quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company’s stock valued at $13,871,000 after buying an additional 86,385 shares during the period. Finally, Fenimore Asset Management Inc bought a new stake in shares of Stevanato Group during the 3rd quarter worth about $12,212,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on STVN shares. UBS Group lowered their price target on Stevanato Group from $23.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday. William Blair cut Stevanato Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Citigroup reduced their price objective on Stevanato Group from $26.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday. Deutsche Bank Aktiengesellschaft started coverage on shares of Stevanato Group in a report on Wednesday, October 7th. They issued a “hold” rating for the company. Finally, Weiss Ratings upgraded shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

About Stevanato Group

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.